Form 4: Kimberly Tzoumakas Acquires Oncology Institute Stock

Kimberly Tzoumakas, a Director at Oncology Institute, Inc., acquired 17,185 shares of common stock on July 7, 2026, through a vested RSU award.

Summary

• Kimberly Tzoumakas, a Director of Oncology Institute, Inc. (TOI), acquired 17,185 shares of common stock.
• The acquisition occurred on July 7, 2026, and was a result of a Restricted Stock Unit (RSU) award that was fully vested upon grant.
• Following this transaction, Tzoumakas beneficially owns 17,185 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a routine transaction of vested stock awards by a director, which is a standard disclosure and does not inherently signal positive or negative performance.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition was through a vested RSU award, indicating compensation for services rendered.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider stock acquisitions, particularly by directors, are common disclosures in the healthcare and biotechnology sectors as companies navigate research, development, and commercialization phases. This filing is a routine disclosure under SEC regulations.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of insider confidence, but the direct impact on share price is minimal without further context on the company's performance.

Key Dates

Keywords

Oncology Institute, TOI, Form 4, SEC Filing, Insider Trading, Stock Acquisition, Director, Restricted Stock Unit, RSU